A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 30 May 2017 Status changed from active, no longer recruiting to completed.
- 18 May 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 18 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2018.